文献速递前列腺癌

多参数MRI与MRI靶向活检在放射性复发前列腺癌诊断中的作用:FORECAST试验分析

The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial.
PubMed 文献 · Eur Urol · 2023-09-29

FORECAST为前瞻性队列诊断研究,纳入144例疑似放疗后复发前列腺癌患者,评估多参数MRI及MRI靶向活检对前列腺内复发的诊断价值及局灶消融规划。结果显示MRI患者水平敏感度0.95、特异度0.21,象限水平敏感度0.66、特异度0.54;仅行MRI靶向活检时5/73例(7%)漏诊癌症,43/73例(59%)存在未采样象限的额外肿瘤。

要点

  • MRI患者水平敏感度0.95、特异度0.21;象限水平敏感度0.66、特异度0.54。
  • MRI靶向活检单独漏诊5/73例(7%),59%患者存在未采样象限额外肿瘤。
  • 若计划挽救性局灶消融,作者认为应考虑联合全腺体系统采样。

核心结论

  • 对放疗后复发前列腺癌患者,MRI及MRI靶向活检(联合或不联合病灶周围采样)可在多数患者中诊断出癌症。
  • MRI未检测到的癌症(Likert评分1-2)更小且分级更低。
  • 若计划挽救性局灶消融,仅MRI靶向活检不足以进行前列腺定位,约3/5经MRI靶向活检诊断的复发癌症患者在未采样象限存在额外肿瘤。

研究设计与样本

  • FORECAST(NCT01883128)为前瞻性队列诊断研究,2014至2018年在6个英国中心招募181例疑似放射性复发患者,本文纳入144例。
  • 所有患者接受MRI及5 mm经会阴模板定位穿刺活检,其中84例额外接受MRI靶向活检。
  • MRI Likert评分3-5分视为可疑。

主要发现

  • 144例中111例(77%)活检检出癌症。
  • 患者水平MRI敏感度0.95(95%CI 0.92-0.99)、特异度0.21(95%CI 0.07-0.35)。
  • 前列腺象限水平258/576(45%)象限活检检出癌症,敏感度0.66(95%CI 0.59-0.73)、特异度0.54(95%CI 0.46-0.62)。
  • 象限水平MRI检出肿瘤较MRI未检出肿瘤最大癌芯长度更长(中位差值3 mm[7 vs 4 mm],95%CI 1-4 mm,p<0.001),分级组更高(p=0.002)。
  • 84例接受MRI靶向活检者中73例(87%)诊断为复发癌症;仅MRI靶向活检漏诊5/73例(7%,95%CI 3-15%),策略4漏诊2/73例(3%,95%CI 0-10%),差异4%(95%CI -3-11%,p=0.4);仅MRI靶向活检时43/73例(59%,95%CI 47-69%)存在未采样象限未检出额外肿瘤,策略4降至7/73例(10%,95%CI 4-19%),差异49%(95%CI 36-62%,p<0.0001)。

临床怎么用

  • 作者认为,若计划挽救性局灶消融,仅MRI靶向活检不足以进行前列腺定位。
  • 作者认为,应考虑在MRI靶向活检基础上联合全腺体系统采样,以同时捕获MRI检出和未检出的病变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of multiparametric magnetic resonance imaging (MRI) for detecting recurrent prostate cancer after radiotherapy is unclear. OBJECTIVE: To evaluate MRI and MRI-targeted biopsies for detecting intraprostatic cancer recurrence and planning for salvage focal ablation. DESIGN, SETTING, AND PARTICIPANTS: FOcal RECurrent Assessment and Salvage Treatment (FORECAST; NCT01883128) was a prospective cohort diagnostic study that recruited 181 patients with suspected radiorecurrence at six UK centres (2014 to 2018); 144 were included here. INTERVENTION: All patients underwent MRI with 5 mm transperineal template mapping biopsies; 84 had additional MRI-targeted biopsies. MRI scans with Likert scores of 3 to 5 were deemed suspicious. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: First, the diagnostic accuracy of MRI was calculated. Second, the pathological characteristics of MRI-detected and MRI-undetected tumours were compared using the Wilcoxon rank sum test and chi-square test for trend. Third, four biopsy strategies involving an MRI-targeted biopsy alone and with systematic biopsies of one to two other quadrants were studied. Fisher's exact test was used to compare MRI-targeted biopsy alone with the best other strategy for the number of patients with missed cancer and the number of patients with cancer harbouring additional tumours in unsampled quadrants. Analyses focused primarily on detecting cancer of any grade or length. Last, eligibility for focal therapy was evaluated for men with localised (≤T3bN0M0) radiorecurrent disease. RESULTS AND LIMITATIONS: Of 144 patients, 111 (77%) had cancer detected on biopsy. MRI sensitivity and specificity at the patient level were 0.95 (95% confidence interval [CI] 0.92 to 0.99) and 0.21 (95% CI 0.07 to 0.35), respectively. At the prostate quadrant level, 258/576 (45%) quadrants had cancer detected on biopsy. Sensitivity and specificity were 0.66 (95% CI 0.59 to 0.73) and 0.54 (95% CI 0.46 to 0.62), respectively. At the quadrant level, compared with MRI-undetected tumours, MRI-detected tumours had longer maximum cancer core length (median difference 3 mm [7 vs 4 mm]; 95% CI 1 to 4 mm, p < 0.001) and a higher grade group (p = 0.002). Of the 84 men who also underwent an MRI-targeted biopsy, 73 (87%) had recurrent cancer diagnosed. Performing an MRI-targeted biopsy alone missed cancer in 5/73 patients (7%; 95% CI 3 to 15%); with additional systematic sampling of the other ipsilateral and contralateral posterior quadrants (strategy 4), 2/73 patients (3%; 95% CI 0 to 10%) would have had cancer missed (difference 4%; 95% CI -3 to 11%, p = 0.4). If an MRI-targeted biopsy alone was performed, 43/73 (59%; 95% CI 47 to 69%) patients with cancer would have harboured undetected additional tumours in unsampled quadrants. This reduced but only to 7/73 patients (10%; 95% CI 4 to 19%) with strategy 4 (difference 49%; 95% CI 36 to 62%, p < 0.0001). Of 73 patients, 43 (59%; 95% CI 47 to 69%) had localised radiorecurrent cancer suitable for a form of focal ablation. CONCLUSIONS: For patients with recurrent prostate cancer after radiotherapy, MRI and MRI-targeted biopsy, with or without perilesional sampling, will diagnose cancer in the majority where present. MRI-undetected cancers, defined as Likert scores of 1 to 2, were found to be smaller and of lower grade. However, if salvage focal ablation is planned, an MRI-targeted biopsy alone is insufficient for prostate mapping; approximately three of five patients with recurrent cancer found on an MRI-targeted biopsy alone harboured further tumours in unsampled quadrants. Systematic sampling of the whole gland should be considered in addition to an MRI-targeted biopsy to capture both MRI-detected and MRI-undetected disease. PATIENT SUMMARY: After radiotherapy, magnetic resonance imaging (MRI) is accurate for detecting recurrent prostate cancer, with missed cancer being smaller and of lower grade. Targeting a biopsy to suspicious areas on MRI results in a diagnosis of cancer in most patients. However, for every five men who have recurrent cancer, this targeted approach would miss cancers elsewhere in the prostate in three of these men. If further focal treatment of the prostate is planned, random biopsies covering the whole prostate in addition to targeted biopsies should be considered so that tumours are not missed.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Light A, Kanthabalan A, Otieno M, et al. The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial. Eur Urol. 2023. PMID: 37778954. doi:10.1016/j.eururo.2023.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。